Gerges Mina M, Rumalla Kavelin, Godil Saniya S, Younus Iyan, Elshamy Walid, Dobri Georgiana A, Kacker Ashutosh, Tabaee Abtin, Anand Viay K, Schwartz Theodore H
Departments of1Neurosurgery.
2Department of Neurosurgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
J Neurosurg. 2020 Jan 31;134(2):535-546. doi: 10.3171/2019.11.JNS192457. Print 2021 Feb 1.
Nonfunctioning pituitary adenomas are benign, slow-growing tumors. After gross-total resection (GTR) or subtotal resection (STR), tumors can recur or progress and may ultimately require additional intervention. A greater understanding of long-term recurrence and progression rates following complete or partial resection and the need for further intervention will help clinicians provide meaningful counsel for their patients and assist data-driven decision-making.
The authors retrospectively analyzed their institutional database for patients undergoing endoscopic endonasal surgery (EES) for nonfunctioning pituitary macroadenomas (2003-2014). Only patients with follow-up of at least 5 years after surgery were included. Tumor volumes were measured on pre- and postoperative MRI. Tumor recurrence was defined as the presence of a 0.1-cm3 tumor volume after GTR, and tumor progression was defined as a 25.0% increase in residual tumor after STR.
A total of 190 patients were included, with a mean age of 63.8 ± 13.2 years; 79 (41.6%) were female. The mean follow-up was 75.0 ± 18.0 months. GTR was achieved in 127 (66.8%) patients. In multivariate analysis, age (p = 0.04), preoperative tumor volume (p = 0.03), Knosp score (p < 0.001), and Ki-67 (p = 0.03) were significant predictors of STR. In patients with GTR, the probability of recurrence at 5 and 10 years was 3.9% and 4.7%, and the probability of requiring treatment for recurrence was 0.79% and 1.6%, respectively. In 63 patients who underwent STR, 6 (9.5%) received early postoperative radiation and did not experience progression, while the remaining 57 (90.5%) were observed. Of these, the probability of disease progression at 5 and 10 years was 21% and 24.5%, respectively, and the probability of requiring additional treatment for progression was 17.5% and 21%. Predictors of recurrence or progression in the entire group were Knosp score (p < 0.001) and elevated Ki-67 (p = 0.03). Significant predictors of progression after STR in those who did not receive early radiotherapy were cavernous sinus location (p < 0.05) and tumor size > 1.0 cm3 (p = 0.005).
Following GTR for nonfunctioning pituitary adenomas, the 10-year chance of recurrence is low and the need for treatment even lower. After STR, although upfront radiation therapy may prevent progression, even without radiotherapy, the need for intervention at 10 years is only approximately 20% and a period of observation may be warranted to prevent unnecessary prophylactic radiation therapy. Tumor volume > 1 cm3, Knosp score ≥ 3, and Ki-67 ≥ 3% may be useful metrics to prompt closer follow-up or justify early prophylactic radiation therapy.
无功能垂体腺瘤是良性、生长缓慢的肿瘤。在进行全切除(GTR)或次全切除(STR)后,肿瘤可能复发或进展,最终可能需要额外干预。更深入了解完全或部分切除后的长期复发和进展率以及进一步干预的必要性,将有助于临床医生为患者提供有意义的建议,并辅助基于数据的决策制定。
作者回顾性分析了其机构数据库中因无功能垂体大腺瘤接受鼻内镜手术(EES)的患者(2003 - 2014年)。仅纳入术后至少随访5年的患者。术前和术后MRI测量肿瘤体积。肿瘤复发定义为GTR后肿瘤体积达到0.1 cm³,肿瘤进展定义为STR后残余肿瘤增加25.0%。
共纳入190例患者,平均年龄63.8±13.2岁;79例(41.6%)为女性。平均随访时间为75.0±18.0个月。127例(66.8%)患者实现了GTR。多因素分析中,年龄(p = 0.04)、术前肿瘤体积(p = 0.03)、Knosp评分(p < 0.001)和Ki-67(p = 0.03)是STR的显著预测因素。在GTR患者中,5年和10年复发概率分别为3.9%和4.7%,复发后需要治疗的概率分别为0.79%和1.6%。在63例行STR的患者中,6例(9.5%)术后早期接受放疗且未进展,其余57例(90.5%)进行观察。其中,5年和10年疾病进展概率分别为21%和24.5%,进展后需要额外治疗的概率分别为17.5%和21%。整个队列中复发或进展的预测因素为Knosp评分(p < 0.001)和Ki-67升高(p = 0.03)。未接受早期放疗的患者中,STR后进展的显著预测因素为海绵窦位置(p < 0.05)和肿瘤大小>1.0 cm³(p = 0.005)。
对于无功能垂体腺瘤,GTR后10年复发几率低,治疗需求更低。STR后,虽然 upfront 放疗可能预防进展,但即使不放疗,10年时干预需求仅约20%,可能有必要进行一段时间的观察以避免不必要的预防性放疗。肿瘤体积>1 cm³、Knosp评分≥3和Ki-67≥3%可能是提示更密切随访或证明早期预防性放疗合理的有用指标。